Clinical trials: CDA
Refractory Hematologic Cancer, Allogeneic Stem Cell Transplantation
CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia
For patients with refractory acute leukemia, allogeneic stem cell transplantation is the only curative therapy. Only 20% of patients may achieve long-term survival mostly due to relapse or nor-relapse mortality (NRM).
- Trial name
- NCT03882203
- Testing
- CLAGE-FluBu
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Multiple Sclerosis
Effect of Cladribine Treatment on Microglial Activation in the CNS
To evaluate the effect of cladribine treatment on microglial activation with conventional MRI, QSM-post processing and TSPO-PET imaging in late stage relapsing remitting multiple sclerosis patients.
- Trial name
- CLADPET (NCT04239820)
- Testing
- Imaging
- Where
- Finland
- Volunteers
- 15 people
- Sponsor
- Turku University Hospital
PTSD
Facilitating Transition to Recommended PTSD Treatment
Cognitive processing therapy (CPT) and prolonged exposure therapy (PE) were widely disseminated as recommended posttraumatic stress disorder (PTSD) treatments.
- Trial name
- NCT05165940
- Testing
- Treatment As Usual, New Health Services Intervention
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- VA Office of Research and Development
Peripheral Artery Disease
Telehealth to Improve Functional Status and Quality of Life in Veterans With PAD
The present study aims to increase Veteran access to supervised exercise therapy and expand its role in improving functional status, quality of life, and cardiovascular risk profile of Veterans with PAD.
- Trial name
- MOVE-IT (NCT05048979)
- Testing
- Exercise
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- VA Office of Research and Development
Leukemia, Myeloid, Acute
Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML
This study will evaluate the investigational drug Midostaurin in various doses given with ATRA and CLAG chemotherapy. Midostaurin is a FLT3 inhibitor that is activated or overexpressed in a significant proportion of AML patients.
- Trial name
- CLAG ATRA AML (NCT01161550)
- Testing
- Granulocyte colony-stimulating factor (G-CSF), Cladribine, Cytarabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Washington University School of Medicine
Secondary Acute Myeloid Leukemia
Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia
This phase Ib/II trial finds out the best dose and effect of cladribine and low dose cytarabine when given in combination with uproleselan in treating patients with treated secondary acute myeloid leukemia.
- Trial name
- NCT04848974
- Testing
- Cladribine, Cytarabine, Uproleselan
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Prediabetes
ForgIng New Paths to Prevent DIabeTes (FINDIT)
This study will evaluate the effects of screening for type 2 diabetes mellitus (T2DM) and brief counseling about screening test results on weight and key health behaviors among Veterans with risk factors for T2DM.
- Trial name
- FINDIT (NCT02747108)
- Testing
- Blood Test Group Intervention, Brochure Group Intervention
- Where
- United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
High Risk Acute Myeloid Leukemia, Allogeneic Hematopoeitic Stem Cell Transplantation
CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML
Aim: To evaluated if cladribine based conditioning (CBA) could decrease relapse after haploidentical allogeneic HSCT in high risk and refractory AML patients as compared with fludarabine based conditioning regimen(FBA).
- Trial name
- NCT03384225
- Testing
- Cladribine, Fludarabine, Busulfan
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Anxiety
Reducing Anxiety and Stress in Primary Care Patients
Anxiety is common among primary care patients, but is undertreated. The purpose of this study is to evaluate whether a brief anxiety treatment designed for VA primary care is more effective at reducing anxiety symptoms in…
- Trial name
- NCT03794089
- Testing
- Brief anxiety intervention, Usual PC-MHI care
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- VA Office of Research and Development
Acute Myeloid Leukemia, Adult, Newly Diagnosed
Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia
This prospective, multi-center, randomized, controlled Phase II study is to compare the therapeutic efficacy and side effect of VACl (Venetoclax,Azacitidine,Cladribine) alternating with VACh (Venetoclax,Azacitidine,Chidamide)…
- Trial name
- NCT06532552
- Testing
- VACl, VACh, VACl Alternating With VACh
- Where
- China
- Volunteers
- 172 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Myelodysplastic Syndromes, Myeloproliferative Chronic Myelomonocytic Leukemia
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
To learn if the combination of cladribine, cytarabine, venetoclax, and azacitidine can help to control higher-risk myelodysplastic syndrome (MDS) with excess blasts and/or higher-risk chronic myelomonocytic leukemia (CMML).
- Trial name
- NCT05365035
- Testing
- Cladribine, Cytarabine, Venetoclax
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Sclerosis (MS)
Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)
The objective of this study was to collect data both retrospectively and prospectively in order to evaluate the long-term outcomes, durability of effect, and real-world treatment patterns following treatment with Cladribine…
- Trial name
- NCT03961204
- Testing
- Data Collection
- Where
- 99 sites in United States, Australia and 27 more
- Volunteers
- 662 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Relapsing-Remitting Multiple Sclerosis
Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)
The main purpose of this study was to investigate the effectiveness of cladribine tablets in a UK real-world setting.
- Trial name
- NCT04997148
- Where
- 8 sites in United Kingdom
- Volunteers
- 116 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Lymphoma
Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab
The goal of this clinical research study is to see how well the drugs 2CdA, cyclophosphamide, and rituximab (rituxan) shrink a lymphoma called Waldenstrom's macroglobulinemia.
- Trial name
- NCT00667329
- Testing
- 2CdA, Cyclophosphamide, Rituximab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Hodgkin Lymphoma, Non-hodgkin Lymphoma
Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma
This study is to explore the efficacy and safety of ChiCGB conditioning therapy in patients with high-risk Hodgkin and non-Hodgkin lymphoma.
- Trial name
- NCT03602131
- Testing
- Chidamide, Cladribine, gemcitabine
- Volunteers
- 30 people
- Sponsor
- Sichuan University
Multiple Sclerosis
Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects
The purpose of the study is to assess the influence of pantoprazole on the pharmacokinetic profile of cladribine, especially in terms of extent of absorption of cladribine since pH-modifying drug may potentially affect the…
- Trial name
- NCT00938366
- Testing
- Cladribine, Pantoprazole
- Volunteers
- 18 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Acute Myeloid Leukemia, Myeloid Neoplasm
CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
This phase II trial studies how well CPX-351 or the CLAG-M regimen (consisting of the drugs cladribine, cytarabine, G-CSF, and mitoxantrone) works in treating medically less-fit patients with acute myeloid leukemia or other…
- Trial name
- NCT04195945
- Testing
- Liposome-encapsulated Daunorubicin-Cytarabine, Cladribine, Cytarabine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Sclerosis, Relapsing-Remitting, Vaccine Response Impaired
Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
The primary objective of this study is to characterize the antibody response to seasonal influenza vaccine, in patients with active RRMS, treated with cladribine, compared to control individuals with basic immunomodulatory…
- Trial name
- CIRMS (NCT05019248)
- Testing
- Most recent vaccine to seasonal influenza
- Where
- Germany
- Volunteers
- 260 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
To determine the efficacy of the combination of tagraxofusp, cladribine, and cytarabine.
- Trial name
- NCT06561152
- Testing
- Tagraxofusp, Cladribine (CLAD), Cytarabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
CDA Type I
Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC
Congenital Dyserythropoietic Anemia Type I (CDAI) is a recessive autosomal disease caused by ineffective erythropoiesis that causes Anemia \& accumulation of iron due to increased absorption of iron in the intestine.
- Trial name
- NCT01795794
- Testing
- omeprazole
- Volunteers
- 12 people
- Sponsor
- Soroka University Medical Center